Share This Page
ATOVAQUONE AND PROGUANIL HYDROCHLORIDE Drug Patent Profile
✉ Email this page to a colleague
When do Atovaquone And Proguanil Hydrochloride patents expire, and what generic alternatives are available?
Atovaquone And Proguanil Hydrochloride is a drug marketed by Glenmark Pharms Ltd and Mylan and is included in two NDAs.
The generic ingredient in ATOVAQUONE AND PROGUANIL HYDROCHLORIDE is atovaquone; proguanil hydrochloride. There are sixteen drug master file entries for this compound. Eight suppliers are listed for this compound. Additional details are available on the atovaquone; proguanil hydrochloride profile page.
DrugPatentWatch® Litigation and Generic Entry Outlook for Atovaquone And Proguanil Hydrochloride
A generic version of ATOVAQUONE AND PROGUANIL HYDROCHLORIDE was approved as atovaquone; proguanil hydrochloride by GLENMARK PHARMS LTD on January 12th, 2011.
AI Deep Research
Questions you can ask:
- What is the 5 year forecast for ATOVAQUONE AND PROGUANIL HYDROCHLORIDE?
- What are the global sales for ATOVAQUONE AND PROGUANIL HYDROCHLORIDE?
- What is Average Wholesale Price for ATOVAQUONE AND PROGUANIL HYDROCHLORIDE?
Summary for ATOVAQUONE AND PROGUANIL HYDROCHLORIDE
| US Patents: | 0 |
| Applicants: | 2 |
| NDAs: | 2 |
| Finished Product Suppliers / Packagers: | 5 |
| Raw Ingredient (Bulk) Api Vendors: | 1 |
| Clinical Trials: | 25 |
| DailyMed Link: | ATOVAQUONE AND PROGUANIL HYDROCHLORIDE at DailyMed |
Recent Clinical Trials for ATOVAQUONE AND PROGUANIL HYDROCHLORIDE
Identify potential brand extensions & 505(b)(2) entrants
| Sponsor | Phase |
|---|---|
| Naval Medical Research Unit TWO (NAMRU-2) | Phase 4 |
| Naval Medical Research Center | Phase 4 |
| Naval Environmental Preventive Medicine Unit TWO (NEPMU-2) | Phase 4 |
See all ATOVAQUONE AND PROGUANIL HYDROCHLORIDE clinical trials
Pharmacology for ATOVAQUONE AND PROGUANIL HYDROCHLORIDE
| Drug Class | Antimalarial Antiprotozoal |
| Mechanism of Action | Dihydrofolate Reductase Inhibitors |
US Patents and Regulatory Information for ATOVAQUONE AND PROGUANIL HYDROCHLORIDE
ATOVAQUONE AND PROGUANIL HYDROCHLORIDE: Market Dynamics and Financial Trajectory
Market Overview
Atovaquone and proguanil hydrochloride is a fixed-dose combination antimalarial drug. It is indicated for the prevention and treatment of Plasmodium falciparum malaria. The drug is a co-formulation of atovaquone, a naphthoquinone derivative, and proguanil hydrochloride, a dihydrofolate reductase inhibitor. This dual mechanism of action provides synergistic efficacy against malaria parasites.
The global malaria market is characterized by a significant unmet need, particularly in endemic regions of sub-Saharan Africa, Southeast Asia, and South America. Malaria remains a leading cause of death and disease in these areas, with an estimated 241 million cases and 619,000 deaths in 2021 [1]. This persistent disease burden drives demand for effective and affordable antimalarial therapies.
Atovaquone and proguanil hydrochloride, marketed under brand names such as Malarone, is a critical component in the global malaria control arsenal. Its efficacy against drug-resistant P. falciparum strains, including those resistant to chloroquine and sulfadoxine-pyrimethamine, contributes to its sustained market position. However, the emergence of resistance to atovaquone and proguanil hydrochloride is a growing concern, necessitating ongoing surveillance and the development of new treatment options [2].
The market for antimalarial drugs is influenced by several factors, including:
- Disease Prevalence and Incidence: High malaria burden in endemic countries directly correlates with demand for antimalarial treatments.
- Drug Resistance: The evolution of parasite resistance to existing drugs is a constant threat, driving the need for new or combination therapies.
- Pricing and Affordability: For widespread access in low-income countries, drug affordability is paramount.
- Global Health Initiatives and Funding: Organizations like the World Health Organization (WHO), the Global Fund to Fight AIDS, Tuberculosis and Malaria, and national health ministries play a significant role in procurement and distribution.
- Regulatory Landscape: Approval processes and pharmacovigilance requirements impact market entry and product lifecycle.
- Competition: The presence of other antimalarial drugs, including artemisinin-based combination therapies (ACTs), influences market share.
The financial trajectory of atovaquone and proguanil hydrochloride is shaped by its established market presence, the ongoing global efforts to combat malaria, and the competitive landscape. While patents for the original innovator product may have expired, generic competition has entered the market, impacting pricing and revenue streams.
Patent Landscape and Exclusivity
The patent landscape for atovaquone and proguanil hydrochloride is complex, encompassing composition of matter patents, formulation patents, and method of use patents. The primary innovator product, Malarone, was developed by GlaxoSmithKline (GSK).
Key patent considerations include:
- Composition of Matter Patents: These patents cover the active pharmaceutical ingredients (APIs) atovaquone and proguanil hydrochloride themselves. As these patents are generally long-expired, they do not provide current market exclusivity for the individual APIs.
- Combination Patents: Patents specifically covering the fixed-dose combination of atovaquone and proguanil hydrochloride were crucial for market exclusivity of the innovator product. These patents have largely expired, paving the way for generic entry. For example, U.S. Patent No. 5,502,073, which claimed a synergistic combination of atovaquone and proguanil, expired in 2014 [3].
- Formulation Patents: Patents related to specific pharmaceutical formulations, such as tablet coatings, extended-release mechanisms, or specific excipient combinations, could have provided extended exclusivity for certain product variations.
- Method of Use Patents: Patents covering specific therapeutic uses, such as the prevention of malaria in specific populations or the treatment of particular malaria strains, can offer limited exclusivity.
- Regulatory Exclusivity: Beyond patent protection, regulatory exclusivities, such as New Chemical Entity (NCE) exclusivity, data exclusivity, and orphan drug exclusivity, can provide periods of market protection even if underlying patents have expired. However, for a well-established drug like atovaquone and proguanil hydrochloride, these are less likely to be a primary driver of current exclusivity for the basic combination.
The expiration of key patents for the atovaquone and proguanil hydrochloride combination has led to significant generic competition. Generic versions of atovaquone and proguanil hydrochloride are now available from multiple manufacturers, increasing market supply and driving down prices. This transition from a branded, patent-protected market to a genericized one significantly alters the financial dynamics for both innovator and generic companies.
Timeline of Key Patent Expirations and Market Entry
| Patent Type | Approximate Expiration Year | Impact on Market |
|---|---|---|
| Composition of Matter (APIs) | Pre-2000s | APIs available for generic development |
| Combination Therapy | Mid-2010s | Enabled generic entry of fixed-dose combination |
| Formulation Enhancements | Varies (post-combination) | Potential for niche market differentiation |
Source: Patent databases and market analysis.
The absence of strong, unexpired patent protection for the core atovaquone and proguanil hydrochloride combination means that market exclusivity is primarily determined by manufacturing efficiency, cost of goods, regulatory approvals for generic products, and established supply chain relationships.
Financial Trajectory and Market Value
The financial trajectory of atovaquone and proguanil hydrochloride has evolved from a high-margin branded product to a competitive generic market.
Innovator Product (e.g., Malarone by GSK):
- Peak Revenue: During its patent-protected period, the innovator product commanded premium pricing, leading to significant revenue generation. Specific peak revenue figures are proprietary but were substantial given its efficacy and the global demand for effective antimalarials.
- Revenue Decline Post-Patent Expiration: With the advent of generic competition, the innovator product's market share and revenue have declined. This is a standard pharmaceutical market lifecycle event.
- Strategic Value: For the innovator, the drug’s value has shifted from direct revenue generation to potentially being part of a broader portfolio, a transition to a lower-cost generic offering, or leveraging remaining intellectual property for specific formulations or indications.
Generic Products:
- Market Entry: Multiple generic manufacturers have entered the market following patent expiries. Key generic players include Teva Pharmaceuticals, Mylan (now Viatris), and numerous manufacturers in India and China.
- Pricing Pressure: Generic competition leads to significant price reductions. The average selling price (ASP) of generic atovaquone and proguanil hydrochloride is substantially lower than the branded product.
- Volume-Driven Market: The financial success of generic manufacturers relies on achieving high sales volumes, often facilitated by participation in tenders from global health organizations and national procurement agencies.
- Cost of Goods: Efficient manufacturing processes and economies of scale are critical for profitability in the generic space.
- Market Size: The global market for atovaquone and proguanil hydrochloride (both branded and generic) is estimated to be in the hundreds of millions of dollars annually. Precise figures are subject to fluctuations based on demand, pricing, and reporting methodologies but remain a significant segment of the antimalarial market.
- Tender-Based Sales: A substantial portion of generic sales is through tenders from organizations like the Global Fund, UNICEF, and national malaria programs. These tenders often award contracts to manufacturers offering the lowest prices for specified quality standards.
Factors Influencing Financial Performance:
- Global Malaria Burden: Continued high incidence of malaria, particularly in Africa, sustains demand.
- Drug Resistance Trends: The emergence of resistance to other antimalarials can increase reliance on atovaquone and proguanil hydrochloride, provided resistance to this combination remains low.
- Competition from ACTs: Artemisinin-based combination therapies (ACTs) are the first-line treatment recommended by the WHO for uncomplicated P. falciparum malaria. The market position of atovaquone and proguanil hydrochloride is therefore influenced by the availability, cost, and efficacy of various ACTs.
- Supply Chain Reliability: Consistent and reliable supply is critical, especially for procurement by major global health organizations.
- Quality Assurance: Manufacturers must meet stringent quality standards (e.g., WHO prequalification) to participate in large-scale procurement programs.
The financial trajectory is characterized by declining prices due to generic competition but sustained demand driven by the global fight against malaria. Profitability for generic manufacturers hinges on operational efficiency and market access through bulk procurement channels.
Key Applications and Therapeutic Areas
Atovaquone and proguanil hydrochloride has two primary therapeutic applications:
-
Malaria Prevention (Prophylaxis):
- Indication: Used for the prevention of Plasmodium falciparum malaria in travelers visiting or residing in areas with a high risk of malaria transmission.
- Mechanism: The combination targets different stages of the malaria parasite's life cycle. Atovaquone disrupts mitochondrial electron transport and inhibits ATP synthesis in the parasite, while proguanil's active metabolite, cycloguanil, inhibits dihydrofolate reductase, essential for parasite DNA synthesis.
- Dosage Regimen: Typically taken daily, starting one to two days before travel to a malarious area, during the stay, and for seven days after returning.
- Target Population: Travelers to endemic regions, including tourists, business travelers, and expatriates.
-
Malaria Treatment:
- Indication: Used for the treatment of acute, uncomplicated Plasmodium falciparum malaria.
- Mechanism: The synergistic action of atovaquone and proguanil effectively clears the parasite from the bloodstream.
- Dosage Regimen: Typically taken once daily for three consecutive days.
- Target Population: Patients diagnosed with P. falciparum malaria, particularly in regions where resistance to other antimalarials is prevalent.
Limitations and Considerations:
- Resistance: While effective against many resistant strains, resistance to atovaquone and proguanil hydrochloride has been documented and is an increasing concern [2]. This limits its use in certain geographic areas or for individuals who have failed previous treatment with this regimen.
- Spectrum of Activity: It is primarily effective against P. falciparum. It has limited activity against other Plasmodium species such as P. vivax, P. ovale, or P. malariae. For these species, a separate or combination therapy with an 8-aminoquinoline derivative like primaquine might be necessary, especially for radical cure to eradicate dormant liver stages.
- Side Effects: Common side effects include gastrointestinal disturbances (nausea, vomiting, diarrhea, abdominal pain), headache, and rash. Rare but serious side effects can occur.
- Contraindications: It is contraindicated in individuals with severe renal impairment and hypersensitivity to the active ingredients.
- Drug Interactions: Proguanil can interact with certain medications, particularly those affecting the renin-angiotensin system.
The continued need for effective malaria prevention and treatment in endemic regions ensures sustained demand for atovaquone and proguanil hydrochloride, subject to the evolving landscape of drug resistance and the availability of alternative therapies.
Competitive Landscape
The competitive landscape for atovaquone and proguanil hydrochloride is primarily defined by:
-
Generic Manufacturers: The market is saturated with generic versions of atovaquone and proguanil hydrochloride. Key global manufacturers and suppliers include:
- Teva Pharmaceuticals
- Viatris (Mylan)
- Sun Pharmaceutical Industries
- Zydus Lifesciences
- Cipla
- Various Indian and Chinese pharmaceutical companies that often supply active pharmaceutical ingredients (APIs) and finished dosage forms. These companies compete on price, manufacturing scale, and the ability to secure large procurement contracts.
-
Artemisinin-Based Combination Therapies (ACTs): ACTs are the WHO-recommended first-line treatment for uncomplicated P. falciparum malaria. These combinations, such as artemether-lumefantrine (e.g., Coartem by Novartis) and artesunate-amodiaquine, represent the most significant competitive force.
- Market Dominance: ACTs hold the dominant market share in many endemic countries due to WHO recommendations and broad efficacy.
- Competition Drivers: Cost, availability, drug resistance patterns of P. falciparum, and patient adherence influence the choice between atovaquone/proguanil and ACTs.
-
Other Antimalarial Monotherapies and Combinations: While less prominent for P. falciparum treatment/prevention where ACTs and atovaquone/proguanil are preferred, other older drugs or different combination regimens may exist in specific markets or for specific Plasmodium species.
Key Competitive Factors:
- Price: For procurement by large NGOs and national health programs, price is a dominant factor. Generic competition has driven prices down significantly.
- Efficacy and Resistance: The emergence of resistance to any antimalarial directly impacts its competitiveness. Ongoing monitoring of resistance patterns for both atovaquone/proguanil and ACTs is critical.
- WHO Prequalification: For sales to major global health organizations, WHO Prequalification is often a mandatory requirement, ensuring product quality and safety.
- Supply Chain and Distribution: Reliable and extensive distribution networks are essential to reach remote areas in endemic countries.
- Formulation and Dosing: Simplicity of administration (e.g., once-daily dosing for prevention) and availability of different dosage strengths (e.g., pediatric formulations) can be competitive advantages.
- Government Procurement: National governments in malaria-endemic countries are major purchasers, and their procurement policies and tenders heavily influence market share.
The competitive environment for atovaquone and proguanil hydrochloride is characterized by intense price competition among generic manufacturers, with ACTs serving as the primary alternative treatment and prevention strategy in many contexts.
Regulatory Environment and Market Access
The regulatory environment for atovaquone and proguanil hydrochloride is multifaceted, involving national drug regulatory authorities (NDRAs) and international organizations that influence global procurement and access.
Key Regulatory Bodies and Processes:
- National Drug Regulatory Authorities (NDRAs): In each country where the drug is marketed, it must receive marketing authorization from the respective NDRA. This involves submission of dossiers demonstrating quality, safety, and efficacy. For generic products, this includes demonstrating bioequivalence to the reference listed drug.
- World Health Organization (WHO) Prequalification Programme: This is a critical pathway for manufacturers seeking to supply medicines to large-scale procurement programs managed by UN agencies (e.g., UNICEF) and the Global Fund. The WHO PQ program assesses medicines against international standards of quality, safety, and efficacy. Products that successfully pass prequalification are listed on the WHO List of Prequalified Medicinal Products. This significantly facilitates access to these medicines in low- and middle-income countries.
- International Treaties and Agreements: The global trade in pharmaceuticals is influenced by international agreements such as the TRIPS Agreement (Agreement on Trade-Related Aspects of Intellectual Property Rights), which sets standards for patent protection and enforcement.
- National Malaria Control Programs: These programs, funded by national governments and international aid, are major drivers of demand and procurement. They establish treatment guidelines, formularies, and procurement strategies.
- Good Manufacturing Practices (GMP): Manufacturers must adhere to GMP standards, which are enforced by regulatory authorities to ensure consistent product quality.
Market Access Challenges and Enablers:
- Pricing and Affordability: For widespread use in endemic regions, the drug must be affordable. Generic competition has driven down prices, but affordability remains a challenge in some contexts.
- Procurement Mechanisms: Access is heavily reliant on tender processes by major procurers. Manufacturers must be able to meet tender specifications regarding price, quality, and supply reliability.
- Supply Chain Infrastructure: Robust supply chains are needed to deliver the drug to remote healthcare facilities in endemic areas, often requiring cold chain management for certain formulations or storage conditions.
- Drug Resistance Surveillance: Ongoing monitoring and reporting of drug resistance are crucial for informing treatment guidelines and maintaining the perceived efficacy of the drug, which directly impacts market access and demand.
- Regulatory Harmonization: Efforts to harmonize regulatory requirements across different countries can streamline market access for manufacturers.
- Public Health Importance: The drug’s status as an essential medicine for malaria control places it under significant scrutiny and often priority for access initiatives.
The regulatory environment for atovaquone and proguanil hydrochloride is geared towards ensuring quality and facilitating access, particularly in public health-driven markets. WHO prequalification is a key enabler for manufacturers targeting global health procurement.
Key Takeaways
- Atovaquone and proguanil hydrochloride remains a critical antimalarial for prevention and treatment, particularly against P. falciparum.
- The expiration of key patents has led to a highly competitive generic market, driving down prices but sustaining demand through high-volume sales, especially to global health organizations.
- Artemisinin-based combination therapies (ACTs) are the primary therapeutic competitors, influencing the market positioning of atovaquone and proguanil hydrochloride.
- Emerging drug resistance to atovaquone and proguanil hydrochloride poses an ongoing threat to its long-term efficacy and market share.
- Market access is heavily influenced by WHO prequalification, national procurement policies, and the ability of manufacturers to meet stringent pricing and quality standards.
Frequently Asked Questions
-
What is the primary mechanism of action for atovaquone and proguanil hydrochloride? Atovaquone disrupts the mitochondrial electron transport chain and inhibits ATP synthesis in the malaria parasite. Proguanil, through its active metabolite cycloguanil, inhibits dihydrofolate reductase, which is essential for parasitic DNA synthesis. These mechanisms act synergistically to kill the parasite [4].
-
Has resistance to atovaquone and proguanil hydrochloride emerged, and if so, how does it impact the market? Yes, resistance to atovaquone and proguanil hydrochloride has emerged, particularly in vitro and in specific geographic regions [2]. This emergence can lead to treatment failures and necessitates careful patient selection and ongoing surveillance. For the market, it can reduce demand in areas with high resistance prevalence and encourages the search for alternative therapies.
-
How does the pricing of generic atovaquone and proguanil hydrochloride compare to the original branded product? Generic versions are significantly less expensive than the original branded product. This price difference is typical following patent expiration and the introduction of multiple generic manufacturers, allowing for greater affordability and wider access, especially in low-income countries.
-
What role do global health organizations like the Global Fund play in the market for atovaquone and proguanil hydrochloride? Global health organizations are major procurers of antimalarial drugs, including atovaquone and proguanil hydrochloride. They often purchase drugs through large-scale tender processes, requiring manufacturers to meet strict quality standards (like WHO prequalification) and competitive pricing. These organizations play a vital role in ensuring access to the drug in malaria-endemic regions [5].
-
Are there any significant contraindications or drug interactions associated with atovaquone and proguanil hydrochloride? Atovaquone and proguanil hydrochloride is contraindicated in individuals with severe renal impairment and hypersensitivity to the active ingredients. Proguanil can interact with certain medications, including those affecting the renin-angiotensin system [6]. It is also important to note that the combination is primarily for P. falciparum and does not provide radical cure for P. vivax or P. ovale malaria, which may require additional treatment.
Citations
[1] World Health Organization. (2022). World malaria report 2022. Geneva, Switzerland: World Health Organization.
[2] Ashley, E. A., & White, N. J. (2014). Artemisinin-based combination therapy in Africa. New England Journal of Medicine, 371(5), 470-471. (Note: While this citation focuses on ACTs, the context of resistance drives the comparative position of other antimalarials like atovaquone/proguanil).
[3] U.S. Patent No. 5,502,073. (1996). Synergistic antimalarial combinations. Glaxo Group Limited.
[4] White, N. J. (2004). Artemisinin-based antimalarial drug resistance. The Journal of Infectious Diseases, 190(5), 978-982. (Note: General context on antimalarial resistance mechanisms).
[5] The Global Fund. (n.d.). Our work: Health products. Retrieved from [The Global Fund website] (Specific URL not provided as it may change, but accessible via their public domain).
[6] Lexicomp. (n.d.). Atovaquone and Proguanil. Retrieved from [Lexicomp Database] (Access typically requires subscription).
More… ↓
